The company mainly produces eight kinds of preparations such as tablets, capsules, granules, water injection, powder injection, freeze-dried powder injection, oral liquid and soft capsules, and eight kinds of raw materials such as erythromycin ethylsuccinate, erythromycin, tetracycline hydrochloride, erythromycin phosphate, calcium dobesilate, urapidil, sodium isoVC and armillarisin A, with an annual output of 7 billion tablets, 50 million tablets, 654.38 billion packets of granules and 654.38 billion packets of granules. The international advanced and domestic first-class modern oral liquid and soft capsule production lines imported from the United States, Japan, Germany and Italy produce 20-30 million bottles of oral liquid and 200 million soft capsules annually. The raw materials tetracycline hydrochloride, erythromycin and erythromycin phosphate have passed FDA certification. Among them, tetracycline hydrochloride has been exported to the United States for 22 consecutive years and has also passed the European COS certification. Erythromycin is the first in China to pass FDA certification; It is the first time to develop and produce erythromycin phosphate in China. The production and sales of erythromycin, erythromycin ethylsuccinate, bulk drug and azithromycin freeze-dried powder injection rank first in China, and it is the largest production base of macrolide antibiotics in China.